Privia Health Group, Inc.

Valuation Analysis

About the Company

Privia Health Group, Inc. en bref

Privia Health Group, Inc. (PRVA) is currently trading at 20,63 € with a market capitalization of 2,6 Md €. The trailing P/E ratio stands at 139.24x, with a forward P/E of 21.57x. The 52-week range spans from 16,36 € to 23,11 €; the current price is 10.7% below the yearly high. Year-over-year revenue growth stands at +25.8%. The net profit margin stands at 0.97%.

💰 Dividende

Privia Health Group, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

19 analystes évaluent Privia Health Group, Inc. (PRVA) au consensus : Achat Fort. L'objectif de cours moyen est de 27,39 €, soit un potentiel de +32.75% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,92 € à 34,87 €.

Privia Health Group, Inc. : la thèse d'investissement en détail

Privia Health Group, Inc. (PRVA) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 25.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Strong Buy with an average price target implying roughly 32.75% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

With a net margin of just 0.97%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 54.63x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 21.57x is meaningfully below the trailing 139.24x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 32.75% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Privia Health Group, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.